Ferristatin: A New Small Molecule Inhibitor of Iron Transport

Ferristatin:一种新的铁转运小分子抑制剂

基本信息

项目摘要

DESCRIPTION (provided by applicant): This application addresses the broad Challenge Area 15, Translational Sciences, and specific challenge topic 15-DK-103: Translate discovery of new molecules and pathways in pathogenesis of NIDDK diseases into potential therapies, diagnostics, or research tools. The biochemistry of iron transport is not thoroughly understood. Although iron deficiency is the most prevalent nutritional problem in the U.S., 1 in 20 Caucasians carry genetic variants of HFE alleles that promote susceptibility to iron overload. Thus, there is a need to develop new therapeutic strategies for diseases of both iron deficiency and overload. Through high-throughput fluorescence-based screening, our lab recently discovered that ferristatin (NSC306711) inhibits both of the major iron transport processes that maintain homeostasis: transferrin- mediated iron uptake and non-transferrin-bound iron uptake by Divalent Metal Transporter 1 (DMT1). Chlorazol black (NSC8679) is structurally similar and has comparable effects on transport. This project will further investigate the impact of these two small molecules and related compounds in vivo, on a) pharmacokinetics of intestinal iron uptake to the vasculature; b) iron uptake into erythroid cells and hepatic non-transferrin bound iron uptake; and c) iron homeostasis and reversal of overload. These efforts will further our goals to elucidate the biochemical processes regulating iron homeostasis, and to provide a foundation for the development of targeted small-molecule therapies for states of anemia and hemochromatosis. PUBLIC HEALTH RELEVANCE: Iron deficiency remains the most prevalent nutritional problem in our country, yet recent identification of the gene responsible for hereditary hemochromatosis indicates that 1 in 20 Caucasians carry the defective allele and thus 1 in 400 may be susceptible to iron overload. Increased knowledge about the transport factors and how they protect against iron deficiency and overload is essential to more broadly address these significant health problems.
描述(由申请人提供):本申请涉及广泛的挑战领域15,转化科学和特定的挑战主题15-DK-103:将NIDDK疾病发病机制中的新分子和途径的发现转化为潜在的治疗,诊断或研究工具。铁转运的生物化学尚未完全了解。虽然缺铁是美国最普遍的营养问题,1/20的高加索人携带HFE等位基因的遗传变异,促进对铁过载的易感性。因此,需要开发用于铁缺乏和铁超负荷的疾病的新的治疗策略。通过高通量荧光筛选,我们的实验室最近发现,铁蛋白抑制素(NSC 306711)抑制维持体内平衡的两个主要铁转运过程:转铁蛋白介导的铁摄取和二价金属转运蛋白1(DMT 1)的非转铁蛋白结合铁摄取。氯唑黑(NSC 8679)结构相似,对转运的影响相当。本项目将进一步研究这两种小分子和相关化合物在体内对以下方面的影响:a)肠道铁摄取至脉管系统的药代动力学; B)红系细胞铁摄取和肝脏非转铁蛋白结合铁摄取;以及c)铁稳态和超负荷逆转。这些努力将进一步阐明调节铁稳态的生化过程,并为开发针对贫血和血色病状态的靶向小分子疗法提供基础。 公共卫生关系:铁缺乏仍然是我国最普遍的营养问题,但最近对遗传性血色病基因的鉴定表明,每20名高加索人中就有1人携带缺陷等位基因,因此每400人中就有1人可能易患铁过载。增加对运输因素的了解以及它们如何防止铁缺乏和过载对于更广泛地解决这些重大健康问题至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marianne Wessling-Resnick其他文献

Marianne Wessling-Resnick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marianne Wessling-Resnick', 18)}}的其他基金

Summer Intern Program (SIP) in Environmental Health Sciences
环境健康科学暑期实习生计划(SIP)
  • 批准号:
    8316246
  • 财政年份:
    2011
  • 资助金额:
    $ 47.98万
  • 项目类别:
Summer Intern Program (SIP) in Environmental Health Sciences
环境健康科学暑期实习生计划(SIP)
  • 批准号:
    8216903
  • 财政年份:
    2011
  • 资助金额:
    $ 47.98万
  • 项目类别:
Summer Intern Program (SIP) in Environmental Health Sciences
环境健康科学暑期实习生计划(SIP)
  • 批准号:
    8660697
  • 财政年份:
    2011
  • 资助金额:
    $ 47.98万
  • 项目类别:
Summer Intern Program (SIP) in Environmental Health Sciences
环境健康科学暑期实习生计划(SIP)
  • 批准号:
    8462276
  • 财政年份:
    2011
  • 资助金额:
    $ 47.98万
  • 项目类别:
Summer Intern Program (SIP) in Environmental Health Sciences
环境健康科学暑期实习生计划(SIP)
  • 批准号:
    8843853
  • 财政年份:
    2011
  • 资助金额:
    $ 47.98万
  • 项目类别:
Chemical Genetics of Iron Transport
铁转运的化学遗传学
  • 批准号:
    8013461
  • 财政年份:
    2010
  • 资助金额:
    $ 47.98万
  • 项目类别:
HFE: A Genetic Determinant of Olfactory Mn Absorption and Toxicity
HFE:嗅觉锰吸收和毒性的遗传决定因素
  • 批准号:
    7941943
  • 财政年份:
    2009
  • 资助金额:
    $ 47.98万
  • 项目类别:
Chemical Genetics of Iron Transport
铁转运的化学遗传学
  • 批准号:
    7898255
  • 财政年份:
    2009
  • 资助金额:
    $ 47.98万
  • 项目类别:
HFE: A Genetic Determinant of Olfactory Mn Absorption and Toxicity
HFE:嗅觉锰吸收和毒性的遗传决定因素
  • 批准号:
    7713292
  • 财政年份:
    2009
  • 资助金额:
    $ 47.98万
  • 项目类别:
Ferristatin: A New Small Molecule Inhibitor of Iron Transport
Ferristatin:一种新的铁转运小分子抑制剂
  • 批准号:
    7941874
  • 财政年份:
    2009
  • 资助金额:
    $ 47.98万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 47.98万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 47.98万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 47.98万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 47.98万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 47.98万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 47.98万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 47.98万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 47.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 47.98万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 47.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了